Literature DB >> 21764643

Prognostic factors in uterine sarcoma.

Angiolo Gadducci1.   

Abstract

Uterine sarcomas usually have an aggressive clinical behaviour, with great tendency to local and distant spread, with unfavourable clinical outcome, excluding endometrial stromal sarcomas and adenosarcoma. Tumour stage is the strongest prognostic factor for all uterine sarcomas, with 5-year survival of about 50-55% for stage I and 8-12% for more advanced stages. Multivariate analysis of some studies have shown that women with leiomyosarcoma have a poorer survival than those with carcinosarcoma. The key issues that will be discussed include the prognostic relevance of pathological and biological variables other than tumour stage in the different histological subtypes of uterine sarcoma. Immunomarkers for cell proliferation and apoptosis have been tested for the identification of tumours with different clinical behaviour, but they are still subject to research and are not currently used in clinical practice.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21764643     DOI: 10.1016/j.bpobgyn.2011.06.002

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  10 in total

1.  Recurrent renal giant leiomyosarcoma.

Authors:  Salih Erpulat Öziş; Kamil Gülpınar; Zafer Şahlı; Baha Burak Konak; Mete Keskin; Süleyman Özdemir; Ömür Ataoğlu
Journal:  Ulus Cerrahi Derg       Date:  2014-12-25

Review 2.  Highlights from 2017: impactful topics published in the Annals of Nuclear Medicine.

Authors:  Andrea Farolfi; Pietro Ghedini; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-28       Impact factor: 9.236

3.  Surgical Methods for the Treatment of Uterine Fibroids - Risk of Uterine Sarcoma and Problems of Morcellation: Position Paper of the DGGG.

Authors:  M W Beckmann; I Juhasz-Böss; D Denschlag; P Gaß; T Dimpfl; P Harter; P Mallmann; S P Renner; S Rimbach; I Runnebaum; M Untch; S Y Brucker; D Wallwiener
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-02       Impact factor: 2.915

4.  Retrospective analysis of 80 cases with uterine carcinosarcoma, leiomyosarcoma and endometrial stromal sarcoma in China, 1988-2007.

Authors:  Yuan Gao; Hao Meng; Yemin Zhang; Tingting Jiao; Ning Hui
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

5.  Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experience.

Authors:  Kristelle Lusby; Kari Brewer Savannah; Elizabeth G Demicco; Yiqun Zhang; Markus Ph Ghadimi; Eric D Young; Chiara Colombo; Ryan Lam; Tugce E Dogan; Jason L Hornick; Alexander J Lazar; Kelly K Hunt; Matthew L Anderson; Chad J Creighton; Dina Lev; Raphael E Pollock
Journal:  Ann Surg Oncol       Date:  2013-01-20       Impact factor: 5.344

6.  Survival of endometrial cancer patients in Germany in the early 21st century: a period analysis by age, histology, and stage.

Authors:  Tianhui Chen; Lina Jansen; Adam Gondos; Meike Ressing; Bernd Holleczek; Alexander Katalinic; Hermann Brenner
Journal:  BMC Cancer       Date:  2012-03-30       Impact factor: 4.430

7.  Prognostic factors and survival in patients treated surgically for recurrent metastatic uterine leiomyosarcoma.

Authors:  Han L T Hoang; Kelsey Ensor; Gerald Rosen; H Leon Pachter; Joseph S Raccuia
Journal:  Int J Surg Oncol       Date:  2014-06-22

8.  18F-FDG/18F-FES standardized uptake value ratio determined using PET predicts prognosis in uterine sarcoma.

Authors:  Makoto Yamamoto; Tetsuya Tsujikawa; Shizuka Yamada; Tetsuji Kurokawa; Akiko Shinagawa; Yoko Chino; Tetsuya Mori; Yasushi Kiyono; Hidehiko Okazawa; Yoshio Yoshida
Journal:  Oncotarget       Date:  2017-04-04

Review 9.  Role of surgery in gynaecological sarcomas.

Authors:  Valentina Ghirardi; Nicolò Bizzarri; Francesco Guida; Carmine Vascone; Barbara Costantini; Giovanni Scambia; Anna Fagotti
Journal:  Oncotarget       Date:  2019-04-02

10.  Fertility-Sparing Management May Be Considered in Young Women with Uterine Sarcoma.

Authors:  Szymon Piątek; Iwona Szymusik; Anna Dańska-Bidzińska; Mariusz Ołtarzewski; Gabriela Trojan; Mariusz Bidziński
Journal:  J Clin Med       Date:  2022-08-15       Impact factor: 4.964

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.